SSIM
BCAB icon

Sheets Smith Investment Management’s BioAtla BCAB Stock Holding History

Sheets Smith Investment Management’s Portfolio BCAB Stock Details BCAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$46.1K Buy
+1,340
New +$30.9K 0.03% 134

Other funds holding BCAB

ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Sheets Smith Investment Management's BCAB Position: Q3 2025 in Review

Sheets Smith Investment Management opened a new position in BioAtla (BCAB) in Q3 2025: 1,340 shares worth $46.1K. The stake represents 0.03% of the portfolio and ranks #134 among its holdings.

43 funds tracked by Wall St. Rank hold BCAB as of Q3 2025.

  • Sheets Smith Investment Management held 1,340 shares of BioAtla worth $46.1K as of Q3 2025.
  • BioAtla was a new Sheets Smith Investment Management position in Q3 2025.
  • BioAtla made up 0.03% of Sheets Smith Investment Management's portfolio in Q3 2025, its #134 holding.
  • 43 funds tracked by Wall St. Rank held BioAtla as of Q3 2025.

Based on Sheets Smith Investment Management's 13F filing for Q3 2025, filed 8 Oct 2025.